Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.

Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for spinal cord injury (SCI) and age-related macular degeneration (AMD). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product. More >>

Learn more about What Sets Us Apart.

StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Letter to Investors
January 2015  Letter to Investors from CEO Martin McGlynn
Recent News
05/18/15StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., May 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at the 2015 Marcum MicroCap Conference. Management is scheduled to speak at 1:30 p.m. Eastern Daylight Time on Thursday, May 28, at The Grand Hyatt New York Hotel, in the Imperial room, located at 109 E 42nd Street in New York ... 
Printer Friendly Version
05/14/15StemCells, Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study
Sensory gains demonstrate the clinical effect of HuCNS–SC® transplantation Results hold promise for Phase II PathwayTM cervical spinal cord injury study NEWARK, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system, announced today that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the ... 
Printer Friendly Version
05/05/15StemCells, Inc. Reports First Quarter 2015 Financial Results and Provides Business Update
Conference Call to be Hosted May 5, 2015, at 4:30PM EDT (1:30 PM PDT) NEWARK, Calif., May 5, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the first quarter 2015. "StemCells, Inc. continues to make great progress," said Martin McGlynn, CEO of StemCells, Inc. "We have completed the en... 
Printer Friendly Version
04/30/15StemCells, Inc. Announces Webcast to Discuss First Quarter 2015 Financial Results
NEWARK, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that it will release financial results for the first quarter 2015, after the market close on Tuesday, May 5. StemCells will host a conference call and webcast to discuss its results and an update on its business at 1:30 p.m. Pacific Daylight Time ... 
Printer Friendly Version
More >>
Upcoming Events
Webcast ImageWebcast
2015 Marcum MicroCap Conference (Live)
05/28/15 at 1:30 p.m. ET
2015 Marcum MicroCap Conference
LocationNew York, NY
Download Documentation StemCells, Inc. at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)-0.00 (0.00%)
Data as of 05/26/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail

Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet